A Study of HS-20094 in Patients With T2DM

NCT06901648 on ClinicalTrials.gov · last registry update 2025-08-01

An unusually large phase 2: 275 participants, more than double the 110 typical for the stage. The sponsor logged completion for 7 March 2025. Primary outcome, as filed: The change of HbA1c in the patients. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: dulaglutide
Trulicity
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Sponsor type: Industry
Enrollment: 275
Started: 2024-02-06
Primary completion: 2025-03-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

The change of HbA1c in the patients

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.